Insmed 2024年第四季度每股亏损$(1.32),低于$(1.17)的预期;销售额$1.0444亿,高于$1.0179亿的预期

财报速递
20 Feb
Insmed-5.85%Pre-market
Insmed (NASDAQ:INSM) 报告了季度每股亏损$(1.32),比分析师共识预期的$(1.17)低了12.82%。这一亏损相比去年同期的每股亏损$(1.28)减少了3.13%。公司报告的季度销售额为$1.0444亿,高于分析师共识预期的$1.0179亿,增长了2.60%。这相比去年同期的$8369万增长了24.79%。

以上内容来自Benzinga Earnings专栏,原文如下:

Insmed (NASDAQ:INSM) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.17) by 12.82 percent. This is a 3.13 percent decrease over losses of $(1.28) per share from the same period last year. The company reported quarterly sales of $104.44 million which beat the analyst consensus estimate of $101.79 million by 2.60 percent. This is a 24.79 percent increase over sales of $83.69 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."